Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1CNS 1Breast 1

Conditions

Pathologic Processes 1Nervous System Neoplasms 1Nervous System Diseases 1Neoplastic Processes 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioma 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Breast Neoplasms 1Brain Neoplasms 1Brain Diseases 1

Interventions

trametinib 3dabrafenib 3binimetinib 2Trastuzumab 2Paclitaxel 2Nivolumab 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Docetaxel 2ulixertinib 1trastuzumab biosimilar HLX02 1sapanisertib 1romidepsin 1ripretinib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1liposomal doxorubicin 1larotrectinib 1ipatasertib 1glutathione pegylated liposomal doxorubicin 1erdafitinib 1entinostat 1diazepinomicin 1defactinib 1copanlisib 1cobimetinib 1clevudine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × glutathione pegylated liposomal doxorubicin × Thoracic × Clear all
NCT01386580 2015-01-22

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

BBB-Therapeutics B.V.

Phase 1/2 Completed
84 enrolled
BreastCNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases, Glioma, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Nervous System Diseases, Nervous System Neoplasms, Pathologic Processes, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡